tiprankstipranks

Liquidia price target raised to $23 from $20 at Wells Fargo

Wells Fargo analyst Tiago Fauth raised the firm’s price target on Liquidia to $23 from $20 and keeps an Overweight rating on the shares. The firm says that following a lengthy legal battle with United Therapeutics (UTHR), Liquidia (LQDA) received final FDA approval for Yutrepia in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Pricing and label are as expected, and focus shifts to the launch. Wells notes results in November of first full quarter of launch are the next key catalyst.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1